Medtronic Transfer Pricing Case: Methods, Remands, and Penalties

The Medtronic transfer pricing case is a nearly two-decade dispute between the IRS and Medtronic over roughly $1.4 billion in additional tax tied to royalties the company’s U.S. parent charged a Puerto Rico manufacturing subsidiary for 2005 and 2006. It is the largest and longest-running intercompany pricing case in U.S. Tax Court history, and after two Tax Court trials and two Eighth Circuit reversals, it is still unresolved. In September 2025, the Eighth Circuit sent the case back to the Tax Court for a third substantive round, this time with instructions that largely favor the IRS’s preferred pricing method.

What the Fight Is About

Medtronic, the Minneapolis-based medical device maker, operated a Puerto Rico subsidiary called Medtronic Puerto Rico Operations Co., or MPROC. MPROC manufactured Class III cardiac rhythm management devices and leads, among the most heavily regulated products in the industry. Puerto Rico’s corporate tax incentives made keeping profit on MPROC’s books far cheaper than keeping it on the U.S. parent’s.

The U.S. parent licensed its patents, manufacturing know-how, regulatory approvals, trade secrets, and other intellectual property to MPROC under agreements called the Technology Licenses. MPROC paid royalties back to the parent in return. The royalty rate decided how the combined profit from device sales got divided: a lower royalty left more profit in Puerto Rico.

Earlier years had been partly handled through a memorandum of understanding setting wholesale royalty rates of 44% for devices and 26% for leads, but the parties could not agree on applying those rates to 2005 and 2006.¹ The IRS audited and issued a notice of deficiency of roughly $1.4 billion for the two years.

The Legal Rule in Play

Internal Revenue Code Section 482 lets the IRS reallocate income between related entities under common control whenever reallocation is needed to prevent tax evasion or to clearly reflect each entity’s income. For transfers of intangible property, the statute requires that income be “commensurate with the income attributable to the intangible.”²

Treasury regulations put this into practice through the arm’s length standard: the price between related parties must match what unrelated parties would have charged in the same circumstances. The regulations also impose a “best method rule” requiring whichever transfer pricing method produces the most reliable measure of an arm’s length result, judged mainly by comparability and the quality of the data.³ There is no fixed hierarchy of methods. Medtronic and the IRS each insisted a different method was “best,” and the gap between their numbers was enormous.

Medtronic’s Method: Comparable Uncontrolled Transaction

Medtronic argued the most reliable pricing method was the Comparable Uncontrolled Transaction (CUT) method, which prices a controlled deal by reference to a similar deal between unrelated parties. When a close real-world comparable exists, the CUT method is generally viewed as the most direct approach because it draws on an actual market price.⁴

Medtronic’s comparable was the Pacesetter Agreement, under which the U.S. parent had licensed certain cardiac rhythm management patents to Siemens Pacesetter, an unrelated third party. Medtronic’s experts adjusted the Pacesetter numbers for differences in geography, duration, and scope, and concluded the intercompany royalties were consistent with what unrelated parties would negotiate.

The problem was comparability. The Technology Licenses to MPROC covered patents, manufacturing know-how, regulatory approvals, secret processes, technical expertise, and copyrights. The Pacesetter Agreement licensed only patents. And the profit potential was far apart: Pacesetter’s product profit margin averaged 29% from 1993 to 1995, while Medtronic’s averaged 54% during 2005 and 2006. Treasury regulations require comparable intangible property to have “similar profit potential,” and they do not permit adjustments for differences in the intangible property itself, only for differences in the circumstances of the transaction.⁴

The IRS’s Method: Comparable Profits

The IRS rejected the CUT approach and proposed the Comparable Profits Method (CPM). The CPM determines an arm’s length result by comparing the operating profitability of the tested party (MPROC) to a set of unrelated companies performing similar functions, rather than by looking for a comparable license deal.

The IRS treated MPROC as a routine contract manufacturer with limited risk, entitled only to a modest market-rate return on its manufacturing assets. Everything above that routine return would be attributed to the parent’s intellectual property and reallocated to the United States.¹ Using five unrelated companies as benchmarks for MPROC’s routine profit, the CPM allocated nearly all non-routine profit to the parent and produced the $1.4 billion deficiency.

Medtronic pushed back that MPROC was not a simple contract manufacturer. It made Class III devices in a heavily regulated environment, bore meaningful product liability risk, and performed sophisticated quality control that went well beyond routine assembly.

How Each Round Came Out

2016: The Tax Court’s First Decision

In T.C. Memo 2016-112, the Tax Court rejected both sides. It called the IRS’s Section 482 reallocations “arbitrary, capricious, or unreasonable,” faulting the agency’s characterization of MPROC as a routine manufacturer and its choice of comparables. But it also found Medtronic’s CUT analysis unreliable, concluding the company had not made persuasive adjustments to the Pacesetter data.

The court then ran its own analysis. Using Pacesetter as a starting point under a modified CUT approach, it set wholesale royalty rates of 44% for devices and 22% for leads. The result fell between the parties’ positions and substantially cut the proposed deficiency. Both sides appealed.

2018: The Eighth Circuit’s First Remand

The Eighth Circuit vacated the Tax Court’s decision, finding the lower court had not provided enough factual findings for the appellate court to tell whether it had actually applied the best method.⁵ The core criticism was that the Tax Court had substituted its own judgment for the parties’ expert analyses without adequately explaining why. The remand directed additional findings on whether Pacesetter was a valid comparable and whether the court’s chosen method produced the most reliable arm’s length result.

2022: The “Unspecified Method”

In T.C. Memo 2022-84, the Tax Court again rejected both the CUT and the CPM. This time it adopted what it called an “unspecified method” blending elements of both, which Medtronic had offered as a backup to its primary CUT argument. The result was an overall royalty rate of 48.8% for both devices and leads, higher than the first opinion but still well below the IRS’s position. The court found Pacesetter did not qualify as a valid CUT because the intangible property did not have similar profit potential, yet it still used Pacesetter data as one input in the hybrid method. The IRS appealed again.

2025: The Eighth Circuit’s Second Remand

On September 3, 2025, the Eighth Circuit vacated and remanded a second time, and this ruling reshaped the trajectory of the case.¹ The appellate court affirmed that Pacesetter was not a valid CUT: the 29% versus 54% profit-potential gap and the difference between licensing only patents and licensing the full intangible package were too great. Three of the five general comparability factors failed, including similarity of the intangible property itself.

Because Pacesetter failed as a CUT, it also “tainted” the unspecified method, which had leaned on Pacesetter data. The Eighth Circuit held the unspecified method was not the best method either.

What the Tax Court Has Been Told to Do Now

The most consequential part of the 2025 ruling is its treatment of the IRS’s CPM. The Eighth Circuit held the Tax Court had applied the wrong legal standard when it rejected the CPM, in particular by faulting the IRS’s comparables because they “did not make solely Class III medical devices.” Under the CPM, functional similarity matters more than product similarity.¹

The remand instructs the Tax Court to conduct a fresh CPM analysis with specific tasks:

Decide whether the IRS’s five proposed comparable companies are sufficiently similar to MPROC, and if not, whether reliable adjustments can correct the differences.
Make specific findings on how differences in asset composition between MPROC and the comparables affect profit allocation, and whether adjustments can account for them.
Reconsider whether the functions performed by MPROC and the comparables are sufficiently alike under the regulations.
Quantify the product liability risk borne by MPROC versus the comparables, and decide whether any difference is material enough to affect the comparability of profits.

The practical effect is striking. Twice the Tax Court rejected the CPM. The Eighth Circuit has now told it to give the CPM a serious, properly conducted evaluation. The CUT method and the unspecified hybrid are off the table. When the case returns to the Tax Court, the CPM will be the primary methodology on the table.

Penalty Exposure in a Case This Size

Transfer pricing adjustments of this magnitude carry their own penalty regime. Section 6662(e) imposes an accuracy-related penalty of 20% for a substantial valuation misstatement, which applies when the claimed price is 200% or more (or 50% or less) of the correct arm’s length amount, or when the net Section 482 adjustment for the year exceeds the lesser of $5 million or 10% of gross receipts. A gross valuation misstatement, triggering a 40% penalty, applies at 400% (or 25%) or when the net adjustment exceeds the lesser of $20 million or 20% of gross receipts.⁶

On an adjustment above $1 billion, those penalties could add hundreds of millions. The main defense is contemporaneous transfer pricing documentation that meets Treasury Regulation 1.6662-6(d). The documentation must exist when the return is filed, not be assembled during audit, and must be produced within 30 days of an IRS request.⁷⁸

Why the Case Matters Beyond Medtronic

Even without a final answer, the litigation has already changed transfer pricing practice.

The CUT method took a real hit. The 2025 opinion makes clear that comparability under Treasury Regulation 1.482-4(c) is demanding for intangibles, that a large profit-potential gap cannot be papered over with adjustments, and that the intangible property itself must be genuinely comparable before adjustments come into play.¹ A third-party license that covers different IP or shows materially different margins will not hold up as a CUT, however many adjustments are layered on.

The CPM gained ground. The Eighth Circuit’s instruction to evaluate the method properly, and its rejection of a strict product-similarity requirement, signals that profit-based methods remain viable even in complex IP cases when the comparables are functionally similar enough. That is closer to how the IRS typically builds a CPM analysis.

The case also marks the limits of judicial creativity. Twice the Tax Court tried to fashion its own method, and twice the Eighth Circuit sent it back. The best method rule gives courts flexibility, but a court-invented hybrid still needs its own factual and regulatory foundation and cannot borrow from a comparable the court itself found unreliable.³

With the case headed back for a third trial-level proceeding, the stakes are not just Medtronic’s bill for 2005 and 2006. The outcome will influence how multinationals and the IRS negotiate, audit, and litigate intercompany pricing for high-value intangibles for years to come.

1
United States Court of Appeals for the Eighth Circuit. Medtronic Inc and Consolidated Subsidiaries v Commissioner of Internal Revenue (2025)
2
Office of the Law Revision Counsel. 26 USC 482 – Allocation of Income and Deductions Among Taxpayers
3
GovInfo. Treasury Regulation 1.482-1 – In General
4
GovInfo. Treasury Regulation 1.482-4 – Methods to Determine Taxable Income in Connection With a Transfer of Intangible Property
5
United States Court of Appeals for the Eighth Circuit. Medtronic Inc and Consolidated Subsidiaries v Commissioner of Internal Revenue (2018)
6
Office of the Law Revision Counsel. 26 USC 6662 – Imposition of Accuracy-Related Penalty on Underpayments
7
Internal Revenue Service. The Section 6662(e) Substantial and Gross Valuation Misstatement Penalty
8
Internal Revenue Service. Transfer Pricing Documentation Best Practices Frequently Asked Questions